Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 4/20 | 0.38 |
| ▸ | SDCBP | O00560 | 2/20 | 0.38 |
| ▸ | SDC2 | P34741 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23129062 | 0.88 | MAPT (0.40) | MAPTALDH1A1THRBSDCBPSDC2 | |
| SCHEMBL23934357 | 0.88 | ALDH1A1 (0.37) | MAPTALDH1A1THRBSDCBPSDC2 | |
| SCHEMBL24160213 | 0.88 | THRB (0.38) | MAPTALDH1A1THRBSDCBPSDC2 | |
| SCHEMBL13258696 | 0.87 | THRB (0.38) | MAPTALDH1A1THRBSDCBPSDC2 | |
| SCHEMBL26289667 | 0.86 | KMT2A (0.37) | MAPTALDH1A1THRBSDCBPSDC2 | |
| SCHEMBL27370927 | 0.85 | THRB (0.33) | MAPTALDH1A1THRBSDCBPSDC2 | |
| SCHEMBL26443198 | 0.84 | ALDH1A1 (0.36) | MAPTALDH1A1THRBSDCBPSDC2 | |
| SCHEMBL23739470 | 0.84 | LMNA (0.36) | MAPTALDH1A1THRBSDCBPSDC2 | |
| SCHEMBL23739521 | 0.83 | POLB (0.35) | MAPTALDH1A1THRBLMNAMEN1 | |
| SCHEMBL23298823 | 0.83 | KDM4E (0.36) | MAPTALDH1A1THRBSDCBPSDC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-3862348-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | EGFR, ERBB2, ERBB3 | MAPT 2433/4885ALDH1A1 3634/4885THRB 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.